|
Jubilant Life Sciences (Citi) Slow Recovery Off a Torrid Phase |
|
Slow Recovery off a Torrid Phase;Slow Pickup in Growth Rates;Margin Improvement on Services Biz Rebound;Revising Estimates | Date | Rating | Target Price | Recommendation Price | Broker house | | 24 Jun 2011 | buy | 290 (from 462) | 163 | Citi Report | |
|
Jubilant Life Sciences (Emkay) Business getting back to normal– Upgrade to Accumulate |
|
Drug discovery business showing signs of improvement;Generic business to get a boost from new launches in US and Vit B3 scale-up | Date | Rating | Target Price | Recommendation Price | Broker house | | 24 Jun 2011 | accumulate (from Hold) | 208 | 163 | Emkay Report | |
|
Jubilant Life Sciences (Goldman Sachs) Gradual recovery ahead post a tough transition year; maintain Buy |
| Date | Rating | Target Price | Recommendation Price | Broker house | | 16 Jun 2011 | buy | 210 | 165 | Goldman Sachs Report | |
|
jubilant life sciences (Emkay) Pain persists, recovery still few quarters away |
Disappointment continues in Services business and margins pressure in Product business; Long term gain with short term pain
| Date |
Rating |
Target Price |
Recommendation Price |
Broker house |
| 11 May 2011 |
hold (from accumulate) |
144 |
159 |
Emkay Report |
Yahoo Link+NSE Link+Reuters Link+Reuters India Link+Google Link+DSR Search
Reports.DesiStockResearch.com |
|
jubilant life science (emkay) Pain persists, recovery still few quarters away |
|
jubilant life science (Citi) Poor 3Q; Tough Times for Research Services |
| Date |
Rating |
Target Price |
Recommendation Price |
Broker house |
| 15 Feb 2011 |
buy |
?? |
193 |
Citi Report |
Yahoo Link+NSE Link+Reuters Link+Reuters India Link+Google Link+DSR Search
Reports.DesiStockResearch.com |
|
jubilant lifesciences (Citi) A Leading CRAMS Play |
|
Jubilant Life Sciences (emkay) Below estimates; Downgrade earnings |
|
Jubilant Life Sciences (emkay) Below estimates; Downgrade earnings |
|
Jubilant Organosys (Emkay) |
|
Below estimates; maintain |
